AVADEL PHARMACEUTICALS PLC Cash Flow Statement
AVDL / Health Care|12 years of annual SEC 10-K data (FY2013-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 12 fiscal years. All figures from audited SEC 10-K filings.
AVADEL PHARMACEUTICALS PLC used $47M in operating cash flow and negative free cash flow of $47M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$48.8M | -$160.3M | -$137.5M | -$77.3M | $7.0M | -$33.2M | -$95.3M | $68.3M | -$41.3M | $41.8M | -$85.5M | -$42.9M |
| Depreciation & Amortization | $2.7M | $1.8M | $1.5M | $815.0K | $1.7M | $2.5M | $7.4M | $4.9M | $14.5M | $13.1M | $14.1M | $3.1M |
| Operating Cash Flow | -$46.9M | -$128.5M | -$70.3M | -$77.3M | -$48.7M | -$38.3M | -$82.7M | $16.7M | $18.9M | $84.3M | -$10.6M | -$20.7M |
| Capital Expenditures | $0 | $0 | $716.0K | $26.0K | $98.0K | $29.0K | $178.0K | $591.0K | $1.2M | $1.6M | $1.7M | $1.0M |
| Free Cash Flow | -$46.9M | -$128.5M | -$71.0M | -$77.3M | -$48.8M | -$38.4M | -$82.9M | $16.1M | $17.7M | $82.7M | -$12.3M | -$21.7M |
| Share Buybacks | - | - | - | - | $0 | $0 | $27.6M | $22.4M | $0 | $0 | - | - |
| FCF Margin | -27.7% | - | - | - | - | - | - | 9.3% | 11.8% | 47.8% | - | - |